The response rate was 34% and median duration of response of 9.1 months across multiple NRG1 fusion bearing solid tumors (e.g., NSCLC, pancreas cancer, breast cancer, cholangiocarcinoma) [76]. This evidence concerns the gene NRG1 and cholangiocarcinoma.